CD40

CD40

CD40 Informations sur la molécule

Molecule Name
Tumor necrosis factor receptor superfamily member 5
Alias de la molécule
CD40,Bp50,CDW40,MGC9013,TNFRSF5,p50
Drug Development Progress
Nombre de médicaments cliniques46
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 3 Clinical
Alias de la cible
Bp50,CD40 Antigens,CD40,B Cell Surface Antigen CD40,B-Cell Surface Antigen CD40,CDW40,CD40L Receptor,CD40 Molecule,Tumor Necrosis Factor Receptor Superfamily, Member 5,CD40 Molecule, TNF Receptor Superfamily Member 5,TNFRSF5,Tumor Necrosis Factor Receptor Superfamily Member 5,P50,CD40 Antigen,B Cell-Associated Molecule
Contexte de la molécule
CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

CD40 Liste de produits

Species
  • Human(7)
  • Mouse(4)
  • Rhesus macaque(2)
  • Canine(1)
  • Cynomolgus(1)
  • Rabbit(1)
  • Rat(1)
Tag
  • His Tag(8)
  • Fc Tag(4)
  • Fc Tag & Avi Tag(2)
  • His Tag & Avi Tag(2)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(17)
Conjugate
  • Unconjugated(12)
  • Biotin-labeled(4)
  • AF647 Labeled(1)
Grade
  • RUO(17)
Low Endotoxin
  • Yes(5)
  • No(12)
MoleculeCat. No.Product NameEspèceHostStructurePurityActivitySize&PriceAdd to Cart
CD40
Human CD40 / TNFRSF5 Protein, His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$440.00

200ug
CD40
Rat CD40 / TNFRSF5 Protein, His Tag (MALS verified)
Rat
HEK293
MALSSDS-PAGE
ELISA

$315.00

100ug
CD40
Cynomolgus CD40 / TNFRSF5 Protein, His Tag, low endotoxin (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
CD40
HOTAvitag
TN5-H82F9
Biotinylated Human CD40 / TNFRSF5 Protein, Fc,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$360.00

25ug
CD40
HOTAvitag
CD0-H82E8
Biotinylated Human CD40 / TNFRSF5 Protein, Avitag™,His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$375.00

25ug
CD40
Rhesus macaque CD40 / TNFRSF5 Protein, Fc Tag (MALS verified)
Rhesus macaque
HEK293
MALSSDS-PAGE
ELISABLI

$315.00

100ug
CD40
Rhesus macaque CD40 / TNFRSF5 Protein, His Tag (MALS verified)
Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$315.00

100ug
CD40
Canine CD40 / TNFRSF5 Protein, His Tag (MALS verified)
Canine
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
CD40
Human CD40 / TNFRSF5 Protein, Fc Tag, low endotoxin (MALS & BLI verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLIFlow

$360.00

100ug
CD40
Human CD40 / TNFRSF5 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLIFlow

$310.00

100ug
You Have Viewed 1-10 Of 17 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Coopération sous licence

Nom du projetType de médicamentDomain thérapeutiqueIndicationPhaseZone de droits
CD40 mAbMonospecific antibodyOncology/CancerAdvanced solid tumorPhase IGlobal
Nom du projet
CD40 mAb
Type de médicament
Monospecific antibody
Domain thérapeutique
Oncology/Cancer
Indication
Advanced solid tumor
Phase
Phase I
Zone de droits
Global
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
MitazalimabADC-1013; JNJ-7107; JNJ-64457107Phase 3 ClinicalAlligator Bioscience Ab
Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Pancreatic Ductal; Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
CD40L-GVAXGM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSFPhase 2 ClinicalUniversity Of South Florida
Adenocarcinoma; Adenocarcinoma of Lung; Leukemia; Lung Neoplasms; Melanoma; Myelodysplastic Syndromes; Skin Melanoma
Details
BI-655064BI-655064Phase 2 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
Arthritis, Rheumatoid; Lupus Nephritis; Purpura, Thrombocytopenic, Idiopathic
Details
SotigalimabAPX-005M; EPI-0050; APX-005Phase 2 ClinicalEpitomics Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Microsatellite Instability; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Skin Neoplasms; Stomach Neoplasms
Details
IscalimabNVP-CFZ533; OM11-62-MF; CFZ-533Phase 2 ClinicalNovartis Pharma Ag
Arthritis, Rheumatoid; Diabetes Mellitus, Type 1; Graves Disease; Hidradenitis Suppurativa; Lupus Erythematosus, Systemic; Lupus Nephritis; Myasthenia Gravis; Rejection of renal transplantation; Rejection of liver transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome
Details
Anti-CD40 ChiLob7/4 (BioNTech)Phase 2 ClinicalBiontech Se
Head and Neck Neoplasms; Pancreatic Neoplasms
Details
CDX-1140CDX-1140Phase 2 ClinicalCelldex Therapeutics
Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Mouth Neoplasms; Nasopharyngeal Carcinoma; Oral Squamous Cell Carcinoma; Oropharyngeal Neoplasms; Oropharyngeal Squamous Cell Carcinoma (OPSCC); Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uveal melanoma; Waldenstrom Macroglobulinemia
Details
Bleselumab4D-11; ASKP-1240Phase 2 ClinicalKyowa Hakko Kogyo Co Ltd
Glomerulosclerosis, Focal Segmental; Psoriasis; Rejection of renal transplantation; Rejection of organ transplantation
Details
TecaginlimabBNT-312; GEN-1042Phase 2 ClinicalGenmab A/S
Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
MP-0317MP-0317Phase 2 ClinicalMolecular Partners Ag
Biliary Tract Neoplasms; Solid tumours
Details
ABBV-9832ABBV-9832Phase 2 ClinicalAbbvie Inc
Arthritis, Rheumatoid
Details
RavagalimabABBV-323; PR-1629977Phase 2 ClinicalAbbvie Inc
Colitis, Ulcerative; Sjogren's Syndrome
Details
DFI-105DFI105; DFI-105Phase 2 ClinicalDiabetes Free Inc
Diabetes Mellitus, Type 2
Details
SHR-2005SHR2005; SHR-2005Phase 2 ClinicalShanghai Hengrui Pharmaceutical Co Ltd
Urinary Bladder Neoplasms
Details
SV-102SV-102; SV102; SYNC-T SV-102Phase 2 ClinicalSyncromune Inc
Prostatic Neoplasms, Castration-Resistant
Details
SHR-7367SHR7367; SHR-7367Phase 2 ClinicalShanghai Hengrui Pharmaceutical Co Ltd
Neoplasms; Solid tumours
Details
CifurtilimabSEA-1C10; SEA-CD40Phase 2 ClinicalSeagen Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
TQB-2916TQB2916; TQB-2916Phase 2 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Melanoma; Neoplasms; Pancreatic Neoplasms; Sarcoma
Details
MIL-97MIL-97Phase 2 ClinicalBeijing Mabworks Biotech Co Ltd
Pancreatic Neoplasms; Solid tumours
Details
DalnicastobartLVGN7409; LVGN-7409Phase 2 ClinicalLyvgen Biopharma(HK)Ltd
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Papillomavirus Infections; Sarcoma; Solid tumours; Stomach Neoplasms; Uveal melanoma
Details
OPT-101OPT-101Phase 2 ClinicalOp-T LLC
Diabetes Mellitus, Type 1; Pneumonia; Sepsis
Details
2141-V112141-V11Phase 2 ClinicalThe Rockefeller University
Ganglioglioma; Glioblastoma; Glioma; Neoplasms; Prostatic Neoplasms; Skin Neoplasms; Solid tumours; Urinary Bladder Neoplasms
Details
CiltistotugYH003; YH-003Phase 2 Clinical
Carcinoma, Pancreatic Ductal; Melanoma; Pancreatic Neoplasms; Solid tumours
Details
AbiprubartKPL-404Phase 2 ClinicalBeth Israel Deaconess Medical Center
Arthritis, Rheumatoid; Sjogren's Syndrome
Details
NJA-730NJA-730; NJA-730a; NJA-730bPhase 1 ClinicalNapajen Pharma
Autoimmune Diseases
Details
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine)Phase 1 ClinicalBaylor College Of Medicine
Leukemia, Lymphocytic, Chronic, B-Cell
Details
GiloralimabABBV-927Phase 1 ClinicalAbbvie Inc
Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
NG-350ANG-350APhase 1 ClinicalAkamis Bio Ltd
Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Rectal Neoplasms
Details
SL-172154SL-172154; SIRPα -Fc-CD40LPhase 1 ClinicalShattuck Labs Inc
Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
recombinant adenovirus vector vaccine targeting MUC1 (MicroVax)Phase 1 ClinicalMicrovax Llc
Neoplasms
Details
HIV ANTI-CD40.ENV GP140Phase 1 ClinicalLinKinVax
HIV Infections
Details
PeptiCRAd-1Valo-D102; PeptiCRAd-1Phase 1 ClinicalValor Biotherapeutics
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma, Myxoid; Neoplasms; Osteosarcoma; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Triple Negative Breast Neoplasms
Details
CD40xFAP bispecific antibody (Bristol-Myers Squibb Company)Phase 1 ClinicalBristol-Myers Squibb Company
Solid tumours
Details
M-0324M-0324; M0324Phase 1 ClinicalMerck KGaA, Darmstadt, Germany
Neoplasms; Solid tumours
Details
KK-2269KK-2269; KK2269Phase 1 ClinicalKyowa Kirin Inc
Carcinoma, Non-Small-Cell Lung; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms
Details
LNF-1901LNF-1901; LNF1901Phase 1 ClinicalLunan Pharmaceutical Group Co
Neoplasms
Details
B-901B-901; B901Phase 1 ClinicalFutureGen Biopharm (Beijing) Co Ltd
Solid tumours
Details
SHR-1704SHR-1704Phase 1 ClinicalJiangsu Hengrui Medicine Co Ltd
Neoplasms
Details
IMB-071703IMB-071703; IMB071703Phase 1 ClinicalBeijng Immunoah Pharma Tech Co Ltd
Solid tumours
Details
ILB-2101ILB-2101Phase 1 ClinicalInnolake Biopharm (Hangzhou) Co Ltd
Neoplasms
Details
HBM-9027HBM-9027; HBM9027Phase 1 ClinicalHarbour Biomed
Neoplasms; Solid tumours
Details
BSI-038BSI-038Phase 1 ClinicalBiosion Inc
Solid tumours
Details
RO-7300490RO-7300490; RG-6189; FAP-CD40; FAP-huCD40Phase 1 ClinicalF. Hoffmann-La Roche Ltd
Solid tumours
Details
InezetamabAMG-994Phase 1 ClinicalAmgen Inc
Solid tumours
Details
BMS-986325Y 12XX-hz28-P238KPhase 1 ClinicalBristol-Myers Squibb Company
Sjogren's Syndrome
Details
NWY-001(Biocytogen Pharmaceuticals)NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals)Phase 1 Clinical
Hematologic Neoplasms; Neoplasms; Solid tumours
Details
Customer Reviews